THE ARISING · Markets & Strategy
Arrowhead Reports Its Tau-Silencing Drug Lowers Spinal Fluid Tau by Up to 73%
Arrowhead Pharmaceuticals says its tau-silencing drug lowered tau in the fluid around the brain and spine by an average of up to 73% in healthy volunteers. These are company-reported interim figures in healthy people, measured in spinal fluid rather than brain tissue, and they come to us secondhand. They put a different kind of drug into a race where rival approaches have reportedly stumbled.
We could not retrieve the Clinical Trials Arena page or the underlying study. This article rests on research desk notes that summarize the Clinical Trials Arena coverage, and nothing here has been checked against that report or against any paper. Every figure below should be read as reported, not verified.
According to the desk notes, the data are interim results from a Phase I/IIa trial (NCT07221344) of ARO-MAPT, presented at an Arrowhead R&D webinar on October 14, 2026. The drug is described as an RNA interference therapy injected under the skin. It silences the MAPT gene, which makes tau, and is said to lower all six forms of the protein.
The notes report average reductions in spinal fluid tau at day 105 of 40%, 69% and 73% across three dose groups. The best single participant fell 85%. The doses were 2.1 or 6.4 mg/kg on days 1, 8 and 15, or 12.8 mg/kg on days 1 and 15. Tau is said to have stayed lower 90 days after the last dose. Arrowhead says this supports dosing every three months or less often. Most side effects were reportedly mild, Grade 1, and the drug was described as generally well tolerated. We have not seen the safety data.
These results come from healthy volunteers. They suggest the drug reaches its target. They do not show that it helps patients. Arrowhead is now testing it in people with early Alzheimer's in the second part of the trial, which reportedly plans to enroll up to 64 healthy volunteers and 48 patients. CEO Christopher Anzalone is quoted as describing the results as "deep and durable reductions of tau expression in the brain." That is the company's characterization, and we could not verify it against the original coverage.
On the competitive context, the notes say antibody drugs aimed at tau have had setbacks. J&J reportedly dropped posdinemab after a Phase IIb failure. Biogen's antitau drug reportedly missed its main goal at AAIC 2026. Eisai's etalanetug is reportedly in Phase II/III. We have not confirmed these details independently.
The strategic point is our interpretation, not a finding. Antibodies try to clear tau outside cells. Arrowhead's approach lowers how much tau is made in the first place. Whether that difference leads to better clinical outcomes is unknown, and the early data do not answer it. This is the weakest link in the argument: lower spinal fluid tau in healthy people is a biomarker result, and it may not translate into any benefit for patients.
What to watch next
The patient data from the early Alzheimer's part of the trial, and whether lower tau translates into any measurable clinical benefit.
Arrowhead Reports Its Tau-Silencing Drug Lowers Spinal Fluid Tau by Up to 73% EU Drug Committee Backs Lilly's Daily Weight-Loss Pill Foundayo England's Adult Social Care Workforce Grows at Slowest Rate in Four Years BioAge and Deep Origin Launch Multi-Target AI Drug Discovery Collaboration Neko Health Brings $500 Body Scans to US With 300,000-Person Waitlist